Osteoporosis-pseudoglioma syndrome

Edit links
Source: Wikipedia, the free encyclopedia.
For other uses, see OPPG.
Osteoporosis-pseudoglioma syndrome
SpecialtyMedical genetics

Osteoporosis-pseudoglioma syndrome or OPGG is a rare

blindness and severe osteoporosis
alongside seemingly random bone fractures.

Signs and symptoms

It is clinically characterized by severe

childhood, this usually leads to various complications, with the main one being recurrent bone fractures.[1][2]

Another very common symptom is total

blindness
, it usually manifests in two ways:

  • Severe congenital impairment of the vision which progresses into total blindness by adulthood
  • Congenitally normal vision which rapidly progresses into severe visual impairment by early infancy and total blindness by adulthood

Occasional findings include

joint hypermobility, hypotonia,[1] cataracts, microphthalmia, and iris, lens, and vitreous defects.[3]

People with only one copy of the gene mutation involved in this condition (heterozygotes) are at a higher risk of developing

exudative vitreoretinopathy and having low bone density, which can consequently result in osteoporosis.[4]

Complications

This condition, as it was mentioned before, is associated with various complications, most of which are osseous.[1]

They are the following:

Anatomy

Osteoporosis and the complications which are brought to light by it are caused by a decreased level of minerals within the bones.[1]

The visual impairments are caused by a group of ocular conditions known as

pseudoglioma.[1]

Genetics

This condition is caused by autosomal recessive missense mutations in the LRP5 gene, located in the long arm of chromosome 11.[5][6]

This gene normally provides instructions to make a protein that embeds itself in the outer membrane of various cell types. It works alongside a different receptor protein, frizzled-4 (which is made by the

FZD4 gene) to send chemical signams from the outside of the cell to the nucleus of said cell. Both proteins (frizzled-4 and LRP5) participate in the Wnt signaling pathway, which are steps that are involved in the development of cells and tissues, it is important for proliferation (cell division), adhesion (cell attachment), migration (cell movement), etc. The protein LRP5 makes is important for the approppiate development and maintenance of multiple tissues. It is involved in guiding the specialization of retinal cells, in establishing proper blood supply to both the retina and the inner ear, and in regulating bone mineral density, the latter of which give strength to the bones and make them less likely to break.[5]

The mutations in this gene that cause osteoporosis-pseudoglioma either impaire the cells' ability of producing LRP5 protein or they change the single amino acids in the protein. They cannot insert themselves into the outside of the cell, which in turn doesn't let them do their function. Loss-of-function mutations in the LRP5 protein alter the chemical signaling pathways involved in normal bone formation and retinal development, which cause the abnormalities that patients with this condition show.[5]

Diagnosis

This condition can be diagnosed through

radiographs
, and eye exams.

Treatment

Treatment is done on the symptoms themselves.

Prevalence

Worldwide, this condition has an estimated prevalence of 1 out of every 2,000,000 live births.[3][7]

History

It was first discovered in 1972 by Bianchine et al. when they described 3 families with

pseudoglioma, retinoblastoma, and recurrence of bone fractures.[8]

References

  1. ^ a b c d e "Osteoporosis-pseudoglioma syndrome: MedlinePlus Genetics". medlineplus.gov. Retrieved 2022-07-12.
  2. ^ "Osteoporosis-pseudoglioma syndrome — About the Disease — Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Retrieved 2022-07-12.
  3. ^ a b "Orphanet: Osteoporosis pseudoglioma syndrome". www.orpha.net. Retrieved 2022-07-12.
  4. ^ "Osteoporosis Pseudoglioma Syndrome OPPG | Boston Children's Hospital". www.childrenshospital.org. Retrieved 2022-07-12.
  5. ^ a b c "LRP5 gene: MedlinePlus Genetics". medlineplus.gov. Retrieved 2022-07-12.
  6. PMID 16252235
    .
  7. S2CID 241377642
    .
  8. ^ "Entry - #259770 - Osteoporosis-pseudoglioma syndrome; OPPG — OMIM". www.omim.org. Retrieved 2022-07-12.

Further reading

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Osteoporosis-pseudoglioma_syndrome&oldid=1218346820"